MHC Class I Associated Hepatitis B Peptides
AssigneeEmergex Vaccines Holding Ltd.
InventorRamila Philip
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.
Claims13
A pharmaceutical composition comprising a polypeptide, oligopeptide or peptide consisting of 8 to about 30 amino acid residues and comprising a sequence that is selected from the group consisting of:
- (i) SEQ ID NO:
- 1, 3, and 5 to 17;
- and
- (ii) an amino acid sequence that differs from SEQ ID NO:
- 1, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 by no more than one amino acid unit;
- wherein said polypeptide, oligopeptide or peptide binds to one or more class I MHC alleles or can be processed to bind to one or more class I MHC alleles and activate a T lymphocyte.
A method for vaccinating and treating a subject for HBV infection, said infected cells expressing any class I MHC molecule, comprising administering to said subject a composition that binds to class I MHC molecules or can be processed to bind to class I MHC molecules comprising:
- at least one polypeptide comprising an epitopic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17 in an amount sufficient to induce a CTL response to said infected cells;
- or at least one polypeptide comprising an epitopic peptide having no more than one amino acid difference from an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17 in an amount sufficient to induce a CTL response to said infected cells.
A method for vaccinating and treating a subject with HBV infection, said infected cells expressing any class I MHC molecule, said method comprising administering to said subject a composition that binds to class I MHC molecules or can be processed to bind to class I MHC molecules comprising:
- a polynucleotide comprising a nucleic acid sequence encoding:
- at least one polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17 in an amount sufficient to induce a CTL response to said infected cells;
- or
- at least one polypeptide comprising an epitopic peptide comprising no more than one amino acid difference from an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17 in an amount sufficient to induce a CTL response to said infected cells.
A method for generating an immune response ex vivo using T cells from a subject infected with HBV, said method comprising:
- stimulating the production of CTL response for use in passive immunotherapy, wherein said T cells react with at least one polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17;
- or at least one polypeptide comprising no more than one amino acid difference from an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17.
A method for assessing or diagnosing an immune response in a subject infected with HBV or vaccinated for HBV and related viruses said method comprising:
- stimulating the production of CTL response, wherein said T cells react with at least one polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17;
- or at least one polypeptide comprising no more than one amino acid difference from an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, 3, and 5 to 17.
Dependencies are inferred from the claim text.